专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4481199A 1,2,4-Triazole-3-amine and 1,2,4 triazole-3,5-diamine compounds and their pharmaceutical use 失效
标题翻译： 1,2,4-三唑-3-胺和1,2,4-三唑-3,5-二胺化合物及其药物用途
公开(公告)号：US4481199A
公开(公告)日：1984-11-06
申请号：US511234
申请日：1983-07-06
申请人： Linda Carey , Barry J. Price , John W. Clitherow , John Bradshaw , Michael Martin-Smith , David E. Bays , Philip Blatcher
发明人： Linda Carey , Barry J. Price , John W. Clitherow , John Bradshaw , Michael Martin-Smith , David E. Bays , Philip Blatcher
IPC分类号： A61K31/41 , A61K31/443 , A61K31/445 , A61P1/04 , A61P43/00 , C07D249/12 , C07D249/14 , C07D295/096 , C07D307/52 , C07D405/12 , C07D471/04 , C07D405/14
CPC分类号： C07D295/096 , C07D249/14 , C07D471/04
摘要： The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined later.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.
摘要翻译：本发明提供了通式（I）的化合物及其生理学上可接受的盐，水合物和生物前体，其中取代基定义在后面。该化合物显示出作为选择性组胺H2拮抗剂的药理学活性。

2. 发明授权

US4323566A Triazole acylamines, pharmaceutical compositions thereof and method of use thereof 失效
公开(公告)号：US4323566A
公开(公告)日：1982-04-06
申请号：US125847
申请日：1980-02-29
申请人： John W. Clitherow , Barry J. Price , John Bradshaw , Michael Martin-Smith , John W. M. MacKinnon , Duncan B. Judd , Linda Carey
发明人： John W. Clitherow , Barry J. Price , John Bradshaw , Michael Martin-Smith , John W. M. MacKinnon , Duncan B. Judd , Linda Carey
IPC分类号： C07D249/14 , C07D295/096 , C07D307/52 , C07D317/22 , C07D333/36 , C07D403/12 , A61K31/41 , C07D403/14
CPC分类号： C07D295/096 , C07D249/14 , C07D307/52 , C07D317/22 , C07D333/36
摘要： The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same of different, each represent hydrogen, C.sub.1 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, or alkyl substituted by hydroxy, alkoxy, amino alkylamino dialkylamino or cycloalkyl or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom which is oxygen or sulphur;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms,Q represents a furan or thiophene ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5- positions, the furan ring optionally bearing a further substituent R.sub.6 adjacent to the group R.sub.1 R.sub.2 N-Alk, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions;R.sub.6 represents halogen or C.sub.1-4 alkyl which may be substituted by hydroxy or C.sub.1-4 alkoxy;x represents --CH.sub.2 --, --O--, --S--or ##STR2## where R.sub.5 represents hydrogen or methyl; n represents zero, 1 or 2;m represents 2, 3 or 4;R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl with at least two carbon atoms, alkoxyalkyl, or aryl, andR.sub.4 represents hydrogen, alkyl, alkenyl or aralkyl and R.sub.7 represents the group COR.sub.8 where R.sub.8 represents hydrogen, alkyl, aryl, aralkyl, alkoxy, heteroaryl or monocyclic heteroarylalkyl or R.sub.7 represents the group SO.sub.2 R.sub.9 where R.sub.9 represents alkyl or aryl, or R.sub.7 represents the group ##STR3## where Y is oxygen or sulphur and R.sub.10 represents hydrogen, alkyl, cycloalkyl, aryl or aralkyl.The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 - antagonists.

3. 发明授权

US4410523A Heterocyclic derivatives 失效
公开(公告)号：US4410523A
公开(公告)日：1983-10-18
申请号：US199522
申请日：1980-10-22
申请人： William D. Ollis , Barry J. Price , Linda Carey , Roger Hayes , John W. Clitherow , John Bradshaw , John W. M. Mackinnon
发明人： William D. Ollis , Barry J. Price , Linda Carey , Roger Hayes , John W. Clitherow , John Bradshaw , John W. M. Mackinnon
IPC分类号： C07D249/14 , A61K31/395 , C07D249/10
CPC分类号： C07D249/14 , Y10S514/927
摘要： The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, aralkyl, trifluoroalkyl, heteroaralkyl, or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkyamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups, or a hydroxy group and/or may contain another heteroatom selected from oxygen and sulphur;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms and is attached to the cyclohexadiene ring at either the 4- or 5- position;X represents --CH.sub.2 or --O--;m represents 2, 3, 4 or 5 and when X is --O-- the chain (CH.sub.2).sub.m may be interrupted by an oxygen atom provided that there are at least two methylene groups between any two heteroatoms in the moiety --X(CH.sub.2).sub.m NH--;R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, or C.sub.2-6 alkyl substituted by hydroxy or alkoxy; andR.sub.4 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl, acyloxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkyloxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxy or alkoxy or the group NR.sub.5 R.sub.6 whereR.sub.5 represents hydrogen, alkyl, alkyl substituted by hydroxy or C.sub.1-3 alkoxy, alkenyl, aralkyl or heteroaralkyl and R.sub.6 represents any of the groups defined for R.sub.5 or may represent the group COR.sub.7 where R.sub.7 represents hydrogen, alkyl, aryl, aralkyl, alkoxy, heteroaryl or monocyclic heteroaralkyl or R.sub.6 represents the group SO.sub.2 R.sub.8 where R.sub.8 represents alkyl or aryl, or R.sub.6 represents the group ##STR2## where Y is oxygen or sulphur and R.sub.9 represents hydrogen, alkyl, cycloalkyl, aryl or aralkyl,or R.sub.5 and R.sub.6 taken together may represent the group .dbd.CR.sub.10 R.sub.11 where R.sub.10 represents aryl or heteroaryl and R.sub.11 represents hydrogen or alkyl.The compounds show activity as selective histamine H.sub.2 -antagonists.

4. 发明授权

US4777179A Heterocyclic derivatives, processes for the use thereof and pharmaceutical compositions containing them 失效
标题翻译：杂环衍生物，其使用方法和含有它们的药物组合物
公开(公告)号：US4777179A
公开(公告)日：1988-10-11
申请号：US789578
申请日：1985-10-21
申请人： John Bradshaw , Duncan B. Judd , Barry J. Price , John W. Clitherow , John W. M. Mackinnon , Linda Carey , Roger Hayes
发明人： John Bradshaw , Duncan B. Judd , Barry J. Price , John W. Clitherow , John W. M. Mackinnon , Linda Carey , Roger Hayes
IPC分类号： C07D249/14 , C07D333/20 , C07D333/28 , C07D333/32 , C07D333/34 , C07D333/42 , A61K31/445 , A61K31/41 , C07D401/10 , C07D403/12 , C07D403/14 , C07D413/10
CPC分类号： C07D333/32 , C07D333/20 , C07D333/28 , C07D333/34 , C07D333/42
摘要： The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and hydrates thereof, in which one of R.sub.1 and R.sub.2 represents hydrogen, halogen or a C.sub.1-4 alkyl group which may be optionally substituted by hydroxy or C.sub.1-4 alkoxy, and the other represents the group R.sub.4 R.sub.5 NAlk-- in which Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;R.sub.3, which may be in either the 2 or 3-position, represents the ##STR2## where X represents --CH.sub.2 --, --O-- or --S--; n represents zero, 1 or 2;m represents 2, 3 or 4; andR.sub.7 represents hydrogen, alkyl, alkenyl, aralkyl, or C.sub.2-6 alkyl substituted by hydroxy or alkoxy; andR.sub.8 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl, acyloxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkyloxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxy or alkoxy, or the group NR.sub.10 R.sub.11 ; with the provisos thatwhere R.sub.2 represents the group R.sub.4 R.sub.5 Nalk then R.sub.3 is in the 2-position;where R.sub.2 represents hydrogen then R.sub.3 is in the 3-position; andwhere R.sub.2 represents halogen or C.sub.1-4 alkyl optionally substituted by hydroxy or C.sub.1-4 alkoxy, and R.sub.3 is in the 2-position, then R.sub.8 cannot represent amino C.sub.1-6 alkyl, C.sub.1-6 alkylamino C.sub.1-6 alkyl, di-C.sub.1-6 alkylamino C.sub.1-6 alkyl or a group NR.sub.10 R.sub.11.The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.
摘要翻译：本发明提供了通式（I）的化合物及其生理上可接受的盐和水合物，其中R 1和R 2中的一个表示氢，卤素或C 1-4烷基，其可任选被羟基或C1- 4烷氧基，另一个表示R4R5NAlk-基团，其中Alk表示1至6个碳原子的直链或支链亚烷基链; 可以在2或3位的R3表示其中X表示-CH 2 - ， - O-或-S-的。 n表示0，1或2; m表示2,3或4; 并且R 7表示氢，烷基，烯基，芳烷基或被羟基或烷氧基取代的C 2-6烷基; 芳基烷氧基烷基，芳氧基烷基，芳烷氧基烷基，氨基烷基，烷基氨基烷基，二烷基氨基烷基，羟基或烷氧基，或基团NR10R11; R10代表氢，烷基，烯基，芳烷基，条件是其中R2表示基团R4R5Nalk，则R3为2-位; 其中R2表示氢，R3表示3-位; 并且其中R 2表示卤素或任选被羟基或C 1-4烷氧基取代的C 1-4烷基，且R 3在2-位，那么R 8不能代表氨基C 1-6烷基，C 1-6烷基氨基C 1-6烷基， C 1-6烷基氨基C 1-6烷基或基团NR 10 R 11。式（I）化合物显示作为选择性组胺H2拮抗剂的药理活性。

5. 发明授权

US4318913A 1,2,4-Triazole-3,5-diamine derivatives 失效
标题翻译： 1,2,4-三唑-3,5-二胺衍生物
公开(公告)号：US4318913A
公开(公告)日：1982-03-09
申请号：US33508
申请日：1979-04-26
申请人： John W. Clitherow , John Bradshaw , John W. M. Mackinnon , Barry J. Price , Michael Martin-Smith , Duncan B. Judd
发明人： John W. Clitherow , John Bradshaw , John W. M. Mackinnon , Barry J. Price , Michael Martin-Smith , Duncan B. Judd
IPC分类号： C07D209/48 , C07D249/14 , C07D307/52 , C07D317/12 , A61K31/445 , A61K31/41 , C07D403/12 , C07D403/14
CPC分类号： C07D209/48 , C07D249/14 , C07D307/52 , C07D317/12 , Y10S514/926 , Y10S514/927
摘要： The invention relates to compounds of the formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2 represent hydrogen, an aliphatic or cycloaliphatic group, or R.sub.1 and R.sub.2 together with the nitrogen atom form a 5 to 10 membered heterocyclic ring:Alk represents a straight or branched alkylene chain;Q represents furan, thiophen or benzene ring which is incorporated into the rest of the molecule;X represents --CH.sub.2 --, ##STR2## --O-- or --S-- whereR.sub.6 represents hydrogen or methyl;n represents zero, 1 or 2;m represents 2, 3 or 4;R.sub.3 represents hydrogen, a substituted or unsubstituted aliphatic or aryl group and;R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, a substituted or unsubstituted aliphatic, aryl, or together with the nitrogen atom form a heterocyclic group.
摘要翻译：本发明涉及式（I）化合物及其生理学上可接受的盐，水合物和生物前体，其中R 1和R 2表示氢，脂族或脂环族基团，或R 1和R 2与氮原子一起形成5至10元杂环：Alk表示直链或支链亚烷基链; Q表示呋喃，噻吩或苯环，其结合到分子的其余部分中; X表示-CH 2 - ， -O-或-S-，其中R 6表示氢或甲基; n表示0，1或2; m表示2,3或4; R 3表示氢，取代或未取代的脂族或芳基， R 4和R 5可以相同或不同，各自表示氢，取代或未取代的脂族基，芳基或与氮原子一起形成杂环基。

6. 发明授权

US4442110A 1H-1,2,4-Triazole-3,5-diamine derivatives and use as selective histamine H.sub.2 -antagonists 失效
公开(公告)号：US4442110A
公开(公告)日：1984-04-10
申请号：US324440
申请日：1981-11-24
申请人： John W. Clitherow , John Bradshaw , John W. M. Mackinnon , Barry J. Price , Michael Martin-Smith , Duncan B. Judd
发明人： John W. Clitherow , John Bradshaw , John W. M. Mackinnon , Barry J. Price , Michael Martin-Smith , Duncan B. Judd
IPC分类号： C07D209/48 , C07D249/14 , C07D307/52 , C07D317/12 , A01N43/64
CPC分类号： C07D209/48 , C07D249/14 , C07D307/52 , C07D317/12 , Y10S514/926 , Y10S514/927
摘要： The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R.sub.7 adjacent to the group R.sub.1 R.sub.2 N-Alk-, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions;R.sub.7 represents halogen or C.sub.1-4 alkyl which may be substituted by hydroxy or C.sub.1-4 alkoxy;X represents --CH.sub.2 --, ##STR2## --O-- or --S-- whereR.sub.6 represents hydrogen or methyl;n represents zero, 1 or 2;m represents 2, 3 or 4;R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl having at least two carbon atoms, alkoxyalkyl or aryl; andR.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, alkyl, alkyl substituted by hydroxy or C.sub.1-3 alkoxy, alkenyl, aralkyl or heteroaralkyl or R.sub.4 and R.sub.5 may together with the nitrogen atom to which they are attached form a 5 to 7-membered saturated heterocyclic ring which may contain another heteroatom, or the group ##STR3## or R.sub.4 and R.sub.5 taken together may represent the group .dbd.CR.sub.8 R.sub.9 where R.sub.8 represents aryl or heteroaryl and R.sub.9 represents hydrogen or alkyl.Preferably when X represents an oxygen atom or ##STR4## and n is zero, then Q only represents a benzene ring. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

7. 发明授权

US4524071A Pyrimidone derivatives 失效
标题翻译：嘧啶衍生物
公开(公告)号：US4524071A
公开(公告)日：1985-06-18
申请号：US58256
申请日：1979-07-17
申请人： Barry J. Price , John W. Clitherow , John Bradshaw , Michael Martin-Smith , Duncan B. Judd , Roger Hayes
发明人： Barry J. Price , John W. Clitherow , John Bradshaw , Michael Martin-Smith , Duncan B. Judd , Roger Hayes
IPC分类号： A61K31/505 , A61P27/16 , A61P29/00 , A61P37/08 , C07D213/65 , C07D215/12 , C07D239/46 , C07D239/47 , C07D239/56 , C07D307/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/12 , C07D405/14 , C07D409/14
CPC分类号： C07D239/47 , C07D213/65 , C07D215/12 , C07D239/56 , C07D307/52
摘要： Compounds of the formula (I) ##STR1## in which R.sub.1 and R.sub.2 each may represent hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, or alkyl, substituted by hydroxy, C.sub.1-3 alkoxy, amino, C.sub.1-3 alkylamino or di-C.sub.1-3 alkylamino or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form an alicyclic heterocyclic ring which may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom are described.Alk is a straight lower alkylene chain,Q is a furan or thiophen ring, the furan ring optionally bearing a further substituent R.sub.5 adjacent to the group R.sub.1 R.sub.2 NAlk-- or Q represents a benzene ring.R.sub.5 represents halogen or C.sub.1-3 alkyl which may be substituted by a hydroxy or C.sub.1-3 alkoxy group;X represents --CH.sub.2 --, --O-- or --S--;n represents zero or 1;m represents 2, 3 or 4;Y represents .dbd.O or .dbd.S;R.sub.3 represents hydrogen in which case R.sub.4 represents methyl or R.sub.3 represents --(CH.sub.2).sub.p V(CH.sub.2).sub.q Ar, phenyl, or alkyl in which case R.sub.4 represents hydrogen;V represents --CH.sub.2 --, --O--, or --S--;p represents zero, 1, 2 or 3;q represents zero, 1, 2 or 3;the sum of p+q being 3 or less;Ar represents an aromatic carbocyclic or heterocyclic ring being optionally substituted by at least one C.sub.1-3 alkyl, C.sub.1-3 alkoxy C.sub.1-3 alkyl, hydroxy, C.sub.1-3 alkoxy, methylenedioxy, halogen, trifluoromethyl or di-C.sub.1-3 alkylamino group;except that when n is zero and X is oxygen then Q represents a benzene or thiophen ring. The compounds of formula (I) have pharmacological activity as selective histamine H.sub.2 -antagonists.
摘要翻译：式（I）的化合物其中R 1和R 2各自可以表示被羟基，C 1-3烷氧基，氨基，C 1-3取代的氢，烷基，环烷基，烯基，炔基，芳烷基或烷基烷基氨基或二-C 1-3烷基氨基或R 1和R 2与它们所连接的氮原子一起形成脂环族杂环，其可以是未取代的或可以被一个或多个C 1-3烷基或羟基和/ 或可以含有另外的杂原子。 Al是直链亚烷基链，Q是呋喃或噻吩环，呋喃环任选带有与R1R2NAlk-基团相邻的另外的取代基R5，或Q表示苯环。 R5表示可被羟基或C1-3烷氧基取代的卤素或C1-3烷基; X表示-CH 2 - ， - O-或-S-; n表示0或1; m表示2,3或4; Y表示= O或= S; R 3表示氢，在这种情况下，R 4表示甲基或R 3表示 - （CH 2）p V（CH 2）qAr，苯基或烷基，在这种情况下，R 4表示氢; V表示-CH 2 - ， - O-或-S-; p代表零，1,2或3; q表示零，1,2或3; p + q的和为3以下; Ar表示任选被至少一个C 1-3烷基，C 1-3烷氧基C 1-3烷基，羟基，C 1-3烷氧基，亚甲二氧基，卤素，三氟甲基或二-C 1-3烷基氨基取代的芳族碳环或杂环; 除了当n为0且X为氧时，Q表示苯或噻吩环。式（I）化合物具有作为选择性组胺H2拮抗剂的药理学活性。

8. 发明授权

US4279911A Amine derivatives and pharmaceutical compositions containing them 失效
标题翻译：胺衍生物和含有它们的药物组合物
公开(公告)号：US4279911A
公开(公告)日：1981-07-21
申请号：US157203
申请日：1980-06-06
申请人： Michael Martin-Smith , Barry J. Price , John Bradshaw , John W. Clitherow
发明人： Michael Martin-Smith , Barry J. Price , John Bradshaw , John W. Clitherow
IPC分类号： A61K31/34 , A61K31/341 , A61K31/345 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/495 , A61K31/505 , A61P1/04 , C07C67/00 , C07C209/00 , C07C209/60 , C07C211/29 , C07C217/48 , C07C261/04 , C07C275/32 , C07C301/00 , C07C303/36 , C07C303/40 , C07C311/64 , C07C313/00 , C07C323/29 , C07C323/44 , C07C323/47 , C07C323/48 , C07C325/00 , C07C335/08 , C07D209/48 , C07D213/32 , C07D295/096 , C07D307/28 , C07D307/38 , C07D307/52 , C07D333/20 , C07D405/12 , C07D409/12 , A61K31/44 , C07D213/58 , C07D307/54
CPC分类号： C07D209/48 , C07D213/32 , C07D295/096 , C07D307/52 , C07D333/20 , Y10S514/826 , Y10S514/887 , Y10S514/925 , Y10S514/926 , Y10S514/927
摘要： The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, N-oxides, hydrates and bioprecursors thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl; R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen lower alkyl, cycloalkyl, lower alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl substituted by hydroxy, lower alkoxy, amine, lower alkylamino or dialkylamino, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring which may contain other heteroatoms or the group ##STR2## where R.sub.4 represents hydrogen or lower alkyl;Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, or a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions;X represents --CH.sub.2 --, --O-- or --S--;n represents zero, 1 or 2;m represents 2, 3 or 4;Alk represents a straight chain alkylene group of 1 to 3 carbon atoms; (except that n is not zero when X is oxygen and Q is a furan or thiophen ring system);q represents 2, 3 or 4 or can additionally represent zero or 1 when E is a --CH.sub.2 -group;p represents zero, 1 or 2;E represents --CH.sub.2 --, --O-- or --S--; andZ represents a monocyclic 5 or 6 membered carbocyclic or heterocyclic aromatic ring which may be optionally substituted by one or more groups or Z represents the group ##STR3## where Q' represents any of the rings defined for Q; Alk' represents any of the groups defined for Alk; and R.sub.5 and R.sub.6, which may be the same or different, each represent any of the groups defined for R.sub.1 and R.sub.2 ; (except that p is not zero when E is oxygen and Q' or Z is a furan or thiophen ring system).The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

9. 发明授权

US4233302A Amine derivatives and pharmaceutical compositions containing them 失效
公开(公告)号：US4233302A
公开(公告)日：1980-11-11
申请号：US970534
申请日：1978-12-18
申请人： Michael Martin-Smith , Barry J. Price , John Bradshaw , John W. Clitherow
发明人： Michael Martin-Smith , Barry J. Price , John Bradshaw , John W. Clitherow
IPC分类号： A61K31/34 , A61K31/341 , A61K31/345 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/495 , A61K31/505 , A61P1/04 , C07C67/00 , C07C209/00 , C07C209/60 , C07C211/29 , C07C217/48 , C07C261/04 , C07C275/32 , C07C301/00 , C07C303/36 , C07C303/40 , C07C311/64 , C07C313/00 , C07C323/29 , C07C323/44 , C07C323/47 , C07C323/48 , C07C325/00 , C07C335/08 , C07D209/48 , C07D213/32 , C07D295/096 , C07D307/28 , C07D307/38 , C07D307/52 , C07D333/20 , C07D405/12 , C07D409/12 , A61K31/44 , C07D213/58 , C07D307/54
CPC分类号： C07D209/48 , C07D213/32 , C07D295/096 , C07D307/52 , C07D333/20 , Y10S514/826 , Y10S514/887 , Y10S514/925 , Y10S514/926 , Y10S514/927
摘要： The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, N-oxides, hydrates and bioprecursors thereof, in whichY represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl;R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen lower alkyl, cycloalkyl, lower alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl substituted by hydroxy, lower alkoxy, amine, lower alkylamino or dialkylamino, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring which may contain other heteroatoms or the group ##STR2## where R.sub.4 represents hydrogen or lower alkyl; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, or a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions;X represents --CH.sub.2, --O-- or --S--;n represents zero, 1 or 2;m represents 2, 3 or 4;Alk represents a straight chain alkylene group of 1 to 3 carbon atoms; (except that n is not zero when X is oxygen and Q is a furan or thiophen ring system)q represents 2, 3 or 4 or can additionally represent zero or 1 when E is a --CH.sub.2 -group;p represents zero, 1 or 2;E represents --CH.sub.2 --, --O-- or --S--; andZ represents a monocyclic 5 or 6 membered carbocyclic or heterocyclic aromatic ring which may be optionally substituted by one or more groups or Z represents the group ##STR3## where Q' represents any of the rings defined for Q; Alk' represents any of the groups defined for Alk; andR.sub.5 and R.sub.6, which may be the same or different, each represent any of the groups defined for R.sub.1 and R.sub.2 ; (except that p is not zero when E is oxygen and Q' or Z is a furan or thiophen ring system).The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

10. 发明授权

US4764612A 3-[3-[1-piperidinylmethyl]phenoxy]propanamine 失效
标题翻译： 3- [3- [1-哌啶基甲基]苯氧基]丙胺
公开(公告)号：US4764612A
公开(公告)日：1988-08-16
申请号：US826832
申请日：1986-02-06
申请人： John W. Clitherow , John Bradshaw , John W. M. Mackinnon , Barry J. Price , Michael Martin-Smith , Duncan B. Judd
发明人： John W. Clitherow , John Bradshaw , John W. M. Mackinnon , Barry J. Price , Michael Martin-Smith , Duncan B. Judd
IPC分类号： C07D209/48 , C07D249/14 , C07D307/52 , C07D317/12 , C07D295/12
CPC分类号： C07D209/48 , C07D249/14 , C07D307/52 , C07D317/12 , Y10S514/926 , Y10S514/927
摘要： The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the variables are as defined in the specification.The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.Also disclosed are intermediates in the preparation of the compounds of the formula (I).
摘要翻译：本发明涉及通式（I）化合物（Ⅰ）及其生理上可接受的盐，水合物和生物前体，其中变量如说明书中所定义。式（I）化合物显示作为选择性组胺H2拮抗剂的药理活性。还公开了制备式（I）化合物的中间体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式